Dr Lal PathLabs

July 26, 2021

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051.

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Subject: Intimation of Conference Call for Investors/Analysts for Q1, FY 22

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015, please find attached the invite of the Conference Call for Investors/Analysts to be held on Friday, July 30, 2021 at 4:30 pm IST to discuss the financial and operating performance for Q1, FY22.

We request you to please take the same on record.

Thanking You,

For Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Dr. Lal PathLabs Limited

Q1 FY22 Earnings Conference Call
Friday, July 30, 2021 at 04:30pm IST

Gurugram, July 26, 2021:

Dr. Lal PathLabs Ltd. (DLPL) will be hosting a conference call to discuss its Q1 FY22 results. DLPL will be represented by (Hony) Brig. Dr. Arvind Lal – Executive Chairman, Dr. Om Prakash Manchanda – Managing Director, Mr. Bharath U – Chief Executive Officer and Mr. Ved Prakash Goel – Chief Financial Officer. We would also have Mr. Rajat Kalra - Company Secretary & Head of Investor Relations.

The conference call will be initiated with a brief discussion by the management on Q1 FY22 financial and operating performance, which will be announced on the same day. Following this, there will be an opportunity for participants to get their queries addressed during the call.

Details of the conference call are as follows:

Time	• **04:30pm IST on Friday, July 30, 2021**
Pre-registration	• To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. • You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call.
Universal Access	• **+91 22 6280 1141** • **+91 22 7115 8042**
Conference dial-in International Toll Number	• **USA – 18667462133**
	• **UK – 08081011573**
	• **Singapore – 8001012045**
	• **Hong Kong – 800964448**
Replay	• **Dial in No. +91 22 71945757 / +91 22 66635757** • **38446 (passcode)** • **Valid from July 30, 2021 to August 06, 2021**

-ENDS-

About Dr. Lal PathLabs Limited (DLPL)

Dr. Lal PathLabs Limited is one of India's leading consumer healthcare brand in diagnostic services.

It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. The catalogue of services includes 471 test panels, 2,590 pathology tests and 1,947 radiology and cardiology tests as on March 31, 2021.

As on March 31, 2021, DLPL's has 231 clinical labs (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,705 Patient Service Centers (PSCs) and 9,247 Pick-up Points (PUPs). In FY20 & FY21, DLPL collected and processed approximately 47.7 million samples and 49.7 million samples from approximately 19.4 million and 20.3 million patients, respectively.

Additional information on Dr. Lal PathLabs Limited:
Corporate Identification No: L74899DL1995PLC065388
Website: https://www.lalpathlabs.com/

For further information, please contact:

Ved Goel / Rajat Kalra
Dr. Lal PathLabs Limited
E-mail:ved.goel@lalpathlabs.com
rajat.kalra@lalpathlabs.com

Siddharth Rangnekar / Nishid Solanki
CDR India
Email: siddharth@cdr-india.com
nishid@cdr-india.com

Disclaimer: *Certain statements that may be made or discussed at the conference call may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like Government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Dr. Lal PathLabs Limited will not be in any way responsible for any action taken based on such statements and discussions and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*